MacroGenics, Inc. (MGNX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-09
How it makes money
It earns by licensing proprietary antibody technology to large pharmaceutical companies and providing contract manufacturing services to partners.
The company monetizes its discovery engine through strategic collaborations where partners pay for the rights to develop and commercialize therapeutic candidates. Additionally, it leverages its Maryland manufacturing facility to provide outsourced services to third parties, which generates revenue to offset facility overhead.
What protects it: the moat
Management claims its competitive advantage relies on proprietary antibody engineering platforms and a portfolio of licensed intellectual property.
The company asserts that its DART and TRIDENT multi-specific antibody platforms provide unique capabilities for developing cancer treatments, which it seeks to protect via patents and licensing agreements with global partners.
What growth costs
It requires substantial and recurring capital for research and development to sustain its drug pipeline and maintain specialized manufacturing capabilities.
Growth depends on the high-cost, high-risk process of clinical trials and preclinical research. Because development cycles are long, the company must continuously consume cash to fund its scientific programs.
What could damage it
Failure to sustain collaborative partnerships or secure additional external funding would likely necessitate the suspension of its clinical development programs.
The business model relies on external non-dilutive capital and the success of partners to advance product candidates; if these relationships dissolve or development milestones fail, the company loses its primary source of cash and pathway to revenue.
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.